{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:46:25Z","timestamp":1794429985243,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018313","name":"Cleveland Eye Bank Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032182","name":"EyePoint Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032182","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["P30EY025585"],"award-info":[{"award-number":["P30EY025585"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ajo.2025.02.025","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T18:54:27Z","timestamp":1740509667000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy"],"prefix":"10.1016","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-5395","authenticated-orcid":false,"given":"Nadia J.","family":"Abbass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7736-7670","authenticated-orcid":false,"given":"Raya","family":"Nahlawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-669X","authenticated-orcid":false,"given":"Jacqueline K.","family":"Shaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4206-9781","authenticated-orcid":false,"given":"Kevin C.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-9515","authenticated-orcid":false,"given":"David C","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0001","first-page":"9","article-title":"Pain in anterior ischemic optic neuropathy","volume":"15","author":"Swartz","year":"1995","journal-title":"J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc"},{"issue":"11","key":"10.1016\/j.ajo.2025.02.025_bib0002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/archopht.1996.01100140566007","article-title":"Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the ischemic optic neuropathy decompression trial","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0004","first-page":"38","article-title":"Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California","volume":"14","author":"Johnson","year":"1994","journal-title":"J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/eye.2014.144","article-title":"Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy","volume":"29","author":"Miller","year":"2015","journal-title":"Eye"},{"issue":"12","key":"10.1016\/j.ajo.2025.02.025_bib0006","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.ophtha.2016.08.017","article-title":"Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Cestari","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.02.025_bib0007","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archopht.1985.01050080048018","article-title":"The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy","volume":"103","author":"Guyer","year":"1985","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.02.025_bib0008","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0002-9394(14)72557-7","article-title":"Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy","volume":"118","author":"Hayreh","year":"1994","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.02.025_bib0009","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9394(14)77911-5","article-title":"Clinical profile and long-term implications of anterior ischemic optic neuropathy","volume":"96","author":"Repka","year":"1983","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.02.025_bib0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00417-008-0981-6","article-title":"Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study","volume":"247","author":"Giambene","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/eye.1995.13","article-title":"Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy","volume":"9","author":"Talks","year":"1995","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.ajo.2025.02.025_bib0012","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0161-6420(99)90159-8","article-title":"Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy","volume":"106","author":"Salomon","year":"1999","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2025.02.025_bib0013","first-page":"1403","article-title":"Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors","volume":"115","author":"Jacobson","year":"1997","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"5","key":"10.1016\/j.ajo.2025.02.025_bib0014","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ophtha.2011.01.054","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients","volume":"118","author":"Lee","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.02.025_bib0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0161-6420(94)31266-8","article-title":"Nonarteritic ischemic optic neuropathy. The impact of tobacco use","volume":"101","author":"Chung","year":"1994","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.025_bib0016","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000027399","article-title":"Role of nocturnal arterial hypotension in optic nerve head ischemic disorders","volume":"213","author":"Hayreh","year":"1999","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2025.02.025_bib0017","first-page":"133","article-title":"Nonarteritic anterior ischemic optic neuropathy associated with chronic anemia: a case series of myelodysplastic syndrome patients","volume":"3","author":"Brouzas","year":"2009","journal-title":"Clin Ophthalmol Auckl NZ"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.025_bib0018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNO.0b013e31828eecbd","article-title":"Nonarteritic anterior ischemic optic neuropathy and obstructive sleep apnea","volume":"33","author":"Bilgin","year":"2013","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ophtha.2003.05.006","article-title":"Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein ib\u03b1 gene","volume":"111","author":"Salomon","year":"2004","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.025_bib0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0161-6420(01)00976-9","article-title":"Sildenafil-associated nonarteritic anterior ischemic optic neuropathy","volume":"109","author":"Pomeranz","year":"2002","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.025_bib0021","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archopht.123.3.400","article-title":"Recurrent visual field defect and ischemic optic neuropathy associated with Tadalafil rechallenge","volume":"123","author":"Bollinger","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.02.025_bib0022","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0002-9394(99)00016-1","article-title":"Features of amiodarone-induced optic neuropathy","volume":"127","author":"Macaluso","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.025_bib0023","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"Controlled trial of 3.0 mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajo.2025.02.025_bib0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2025.02.025_bib0026","unstructured":"FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. FDA. 2024. Accessed December 11, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or"},{"key":"10.1016\/j.ajo.2025.02.025_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ajo.2025.02.025_bib0028","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.025_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"0","key":"10.1016\/j.ajo.2025.02.025_bib0030","article-title":"Comparative effects of glucagon-like peptide 1 receptor agonists and Metformin on glaucoma risk in patients with type 2 diabetes","volume":"0","author":"Muayad","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.02.025_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.02.025_bib0032","article-title":"Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.02.025_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102355","article-title":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms","volume":"69","author":"Ribeiro-Silva","year":"2023","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.ajo.2025.02.025_bib0034","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/met.2022.0004","article-title":"Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome","volume":"20","author":"Premji","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.025_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmacy12010011","article-title":"The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review","volume":"12","author":"Le","year":"2024","journal-title":"Pharmacy"},{"issue":"12","key":"10.1016\/j.ajo.2025.02.025_bib0036","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3390\/biom13121695","article-title":"Beyond the cardiovascular effects of glucagon-like peptide-1 receptor agonists: body slimming and plaque stabilization. Are new statins born?","volume":"13","author":"Lecis","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ajo.2025.02.025_bib0037","article-title":"Validity of administrative coding for nonarteritic ischemic optic neuropathy","author":"Hamedani","year":"2022","journal-title":"J Neuroophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2025.02.025_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:54:27Z","timestamp":1777694067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"alternative-id":["S0002939425000947"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.02.025","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}